Roche Holding (ROG SW): Despite Patent Cliff Growth Momentum to Continue Backed by New Launches

306 Views20 Apr 2022 15:48
  • Roche Holding AG (ROG SW) is well-positioned for single-digit revenue growth, as strong uptake of new products is offsetting revenue loss from patent expired products due to biosimilar competition.
  • New drugs, especially Hemlibra, Ocrevus, and Tecentriq are on a high growth trajectory, which is expected to continue, with no dependency on the COVID-19.
  • Recently, Roche received FDA approvals for two new ophthalmology products. Both of them have potential blockbuster sales opportunity. Two more drugs are expected to be launched this year.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
  • Unlock all research summaries
  • Follow top, independent analysts
  • Receive personalised alerts and emails
  • Access Briefings, Analytics, and Events

Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.

Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.

Already have an account? Sign In Now
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Health CareEquity Bottom-UpThematic (Sector/Industry)
Price Chart(Sign Up to Access)